Incyte (TICKER: INCY) Benchmark And Performance Data

there are 4 of samples in the benchmark for Incyte in year 2022 in 2022. The total inventory for Incyte was $6,967,000.00 in 2018. The total inventory for Incyte was $6,482,000.00 in 2017. The total inventory for Incyte was $406,000.00 in 2013. The total inventory for Incyte was $4,106,000.00 in 2016. The total inventory for Incyte was $358,000.00 in 2014. The total inventory for Incyte was $278,000.00 in 2012. The total inventory for Incyte was $27,904,000.00 in 2021. The total inventory for Incyte was $16,425,000.00 in 2020. The total inventory for Incyte was $11,400,000.00 in 2019. The total inventory for Incyte was $1,783,000.00 in 2015. The sales, general, and administrative (SGA) for Incyte was $85,363,000.00 in 2012. The sales, general, and administrative (SGA) for Incyte was $739,600,000.00 in 2021. The sales, general, and administrative (SGA) for Incyte was $516,900,000.00 in 2020. The sales, general, and administrative (SGA) for Incyte was $468,711,000.00 in 2019. The sales, general, and administrative (SGA) for Incyte was $434,407,000.00 in 2018. The sales, general, and administrative (SGA) for Incyte was $366,286,000.00 in 2017. The sales, general, and administrative (SGA) for Incyte was $303,251,000.00 in 2016. The sales, general, and administrative (SGA) for Incyte was $196,614,000.00 in 2015. The sales, general, and administrative (SGA) for Incyte was $165,772,000.00 in 2014. The sales, general, and administrative (SGA) for Incyte was $109,983,000.00 in 2013. The sales, general, and administrative (SGA) for Incyte was $$1,002,000,000 in 2022. The revenue volatility for Incyte was 20.88% in 2022. The market capitalization for Incyte was $18,544,318,989.00 in 2012. The market capitalization for Incyte was $17,869,229,589.00 in 2018. The market capitalization for Incyte was $17,584,346,461.00 in 2015. The market capitalization for Incyte was $16,855,873,834.00 in 2016. The market capitalization for Incyte was $16,227,597,382.00 in 2014. The market capitalization for Incyte was $16,120,675,346.00 in 2019. The market capitalization for Incyte was $15,192,478,484.00 in 2013. The market capitalization for Incyte was $14,824,390,470.00 in 2017. The market capitalization for Incyte was $13,902,811,042.00 in 2020. The market capitalization for Incyte was $12,945,546,140.00 in 2021. The market capitalization for Incyte was $$13,635,000,000 in 2022. The gross revenue for Incyte was $753,751,000.00 in 2015. The gross revenue for Incyte was $511,495,000.00 in 2014. The gross revenue for Incyte was $354,947,000.00 in 2013. The gross revenue for Incyte was $297,059,000.00 in 2012. The gross revenue for Incyte was $2,986,267,000.00 in 2021. The gross revenue for Incyte was $2,666,702,000.00 in 2020. The gross revenue for Incyte was $2,158,759,000.00 in 2019. The gross revenue for Incyte was $1,881,883,000.00 in 2018. The gross revenue for Incyte was $1,536,216,000.00 in 2017. The gross revenue for Incyte was $1,105,719,000.00 in 2016. The gross revenue for Incyte was $$3,395,000,000 in 2022. The gross margin for Incyte was $17.43% in 2022. The days sales outstanding for Incyte was 68 days in 2022. The days payable outstanding for Incyte was 396 days in 2022. The days of inventory for Incyte was $62 in 2022. The cost of goods sold (COGS) for Incyte was 6.10% in 2022. The cost of goods sold (COGS) for Incyte was $94,123,000.00 in 2018. The cost of goods sold (COGS) for Incyte was $79,479,000.00 in 2017. The cost of goods sold (COGS) for Incyte was $630,000.00 in 2013. The cost of goods sold (COGS) for Incyte was $58,187,000.00 in 2016. The cost of goods sold (COGS) for Incyte was $3,004,000.00 in 2014. The cost of goods sold (COGS) for Incyte was $27,000,000.00 in 2015. The cost of goods sold (COGS) for Incyte was $157,000.00 in 2012. The cost of goods sold (COGS) for Incyte was $151,000,000.00 in 2021. The cost of goods sold (COGS) for Incyte was $131,300,000.00 in 2020. The cost of goods sold (COGS) for Incyte was $114,249,000.00 in 2019. The cost of goods sold (COGS) for Incyte was $$207,000,000 in 2022. The cash to cash cycle time for Incyte was -266 in 2022. The annual percentage growth rate of Incyte was -0.14% in 2022. Incyte in its benchmark peer group, had rank 4 for gross revenue in 2022. Incyte in its benchmark peer group, had rank 3 for sales growth in 2022. Incyte in its benchmark peer group, had rank 3 days for days sales outstanding in 2022. Incyte in its benchmark peer group, had rank 1 for cost of goods sold as a percent of revenue in 2022. Incyte in its benchmark peer group, had rank 1 for cash to cash cycle time in 2022. Incyte in its benchmark peer group, had rank 1 days for days of inventory in 2022. Incyte headquarters region is South. Incyte has ticker symbol INCY. Incyte has the following profile: Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally.. Incyte has primary indstury Biotechnology. Incyte had a $$7,157,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. Incyte had Regeneron Pharmaceuticals, Inc., and Incyte, and Vertex Pharmaceuticals Incorporated, and Moderna benchmark peer companies for its SIC code in 2022. Incyte had 8 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. Incyte had 27.52% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. Incyte had 2,324 number of employees in 2022. Incyte had 0.04% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. Incyte had 0.00% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. Incyte had 0.00% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. Incyte had 0 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. Incyte had 0 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. Incyte can reduce overall cost by $$528,000,000 by improving both COGS and SGA to next benchmark tier in 2022. Incyte can reduce inventory with practices including in 2022. Incyte can reduce days sales outstanding with practices including in 2022. Incyte can increase sales revenue by $$7,157,000,000 improving sales performance to next benchmark tier in 2022. Incyte can increase revenue growth by $$1,000,000 by improving growth performance to next benchmark tier in 2022. Incyte can increase overall revenue by $$7,158,000,000 by improving both growth and sales performance to next benchmark tier in 2022. Incyte can increase days payables outstanding with practices including in 2022. Incyte can increase days payables outstanding by $0 days by increasing days payables outstanding to next benchmark tier in 2022. Incyte can improve total financial performance by $$7,756,000,000 by improving revenue, costs, and working capital in 2022. Incyte can decrease overall working capital by $$70,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. Incyte can decrease inventory days by $0 days by reducing inventory days to next benchmark tier in 2022. Incyte can decrease days sales outstanding by $70,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. Incyte can accelerate revenue growth practices including Revenue-optimized Planning in 2022. Incyte can accelerate revenue growth practices including Pricing Optimization in 2022. Incyte can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 79 days was the measured advantage or top third performance level for days of inventory in Incyte's peer group in 2022. 7.90% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in Incyte's peer group in 2022. 68 days was the measured superior or top ten performance level for days of inventory in Incyte's peer group in 2022. 62 days was the measured advantage or top third performance level for cash to cash cycle time in Incyte's peer group in 2022. 60 days was the measured parity or middle performance level for days sales outstanding in Incyte's peer group in 2022. 52 days was the measured advantage or top third performance level for days sales outstanding in Incyte's peer group in 2022. 49.60% was the measured superior or top ten performance level for gross margin in Incyte's peer group in 2022. 47 days was the measured superior or top ten performance level for days sales outstanding in Incyte's peer group in 2022. 38.48% was the measured parity or middle performance level for sales volatility in Incyte's peer group in 2022. 34.48% was the measured advantage or top third performance level for sales volatility in Incyte's peer group in 2022. 25.42% was the measured superior or top ten performance level for sales volatility in Incyte's peer group in 2022. 12.46% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in Incyte's peer group in 2022. 11.50% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in Incyte's peer group in 2022. 109 days was the measured parity or middle performance level for days of inventory in Incyte's peer group in 2022. 102 days was the measured parity or middle performance level for cash to cash cycle time in Incyte's peer group in 2022. 0.15% was the measured superior or top ten performance level for sales growth in Incyte's peer group in 2022. -157 days was the measured superior or top ten performance level for cash to cash cycle time in Incyte's peer group in 2022. -0.10% was the measured parity or middle performance level for sales growth in Incyte's peer group in 2022. -0.03% was the measured advantage or top third performance level for sales growth in Incyte's peer group in 2022. $48.98% was the measured advantage or top third performance level for gross margin in Incyte's peer group in 2022. $44.95% was the measured parity or middle performance level for gross margin in Incyte's peer group in 2022. $$16,864,000,000 was the measured superior or top ten performance level for gross revenue in Incyte's peer group in 2022. $$12,843,000,000 was the measured advantage or top third performance level for gross revenue in Incyte's peer group. $$10,552,000,000 was the measured parity or middle performance level for gross revenue in Incyte's peer group in 2022.